Dario Surpasses 100 Scientific Studies, Cementing Leadership Among Digital Health's Most Evidence-Based Platforms

Rhea-AI Summary

DarioHealth (NASDAQ: DRIO) announced it has surpassed 100 peer-reviewed studies and conference abstracts as of Jan 21, 2026, reinforcing its evidence base for employers, health plans and members.

The research portfolio includes large study populations, longitudinal designs (some up to two years), independent third-party investigator-initiated studies, and directly observed outcomes such as actual claims reduction and measured HbA1c improvement. Dario says the body of work positions it among the most evidence-based digital health vendors and supports value-based purchasing and vendor consolidation decisions.

Positive

• Surpassed 100 peer-reviewed studies on Jan 21, 2026
• Includes independent third-party investigator-initiated studies
• Contains longitudinal studies spanning up to two years
• Reports directly observed outcomes like claims reduction and HbA1c improvement

Negative

• None.

News Market Reaction

-3.05%

1 alert

-3.05% News Effect

-$3M Valuation Impact

$80M Market Cap

0.1x Rel. Volume

On the day this news was published, DRIO declined 3.05%, reflecting a moderate negative market reaction. This price movement removed approximately $3M from the company's valuation, bringing the market cap to $80M at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Scientific studies: 100+ studies Study duration: Up to 2 years Q3 2025 revenue: $5,007k +5 more

8 metrics

Scientific studies 100+ studies Peer-reviewed publications and conference abstracts milestone

Study duration Up to 2 years Some longitudinal designs in Dario’s research portfolio

Q3 2025 revenue $5,007k Quarterly revenue, down from $7,423k a year ago

Q3 2025 net loss $10,466k Net loss for Q3 2025

Cash & equivalents $31,907k Balance as of September 30, 2025

Long-term loan $30,617k Long‑term loan balance as of September 30, 2025

Registered shares 2,713,180 shares S-3 resale registration filed October 20, 2025

Private placement proceeds $17,500,000 Equity offering reported on Form D in October 2025

Market Reality Check

Price: $11.64 Vol: Volume 7,260 is well belo...

low vol

$11.64 Last Close

Volume Volume 7,260 is well below the 20-day average of 23,545 (relative volume 0.31x). low

Technical Price at 12.44 is trading below the 200-day MA of 12.65 and 29.89% under the 52-week high.

Peers on Argus

DRIO showed 0% move ahead of this news while peers were mixed: several (HCTI -7....

DRIO showed 0% move ahead of this news while peers were mixed: several (HCTI -7.86%, BFRG -5.72%, VSEE -2.7%) were down, with MGRX slightly up (0.64%), suggesting stock-specific rather than sector-driven dynamics.

Historical Context

5 past events · Latest: Dec 10 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Dec 10	AI product launch	Positive	+4.1%	Launch of DarioIQ AI layer for hypertension members in app.
Dec 09	Capital raise	Neutral	+0.1%	Private placement for 2,713,180 shares at $6.45 raising $17.5M.
Dec 04	Clinical outcomes data	Positive	+1.3%	JMIR Cardio study showing sustained blood pressure improvements.
Dec 02	Commercial wins	Positive	+0.8%	79 new client accounts, far exceeding 2025 target.
Nov 24	Cost-savings study	Positive	-7.2%	JMIR study reporting $5,077 annual medical cost savings per user.

Pattern Detected

Recent DRIO news skewed positive, with three recent favorable platform/AI and client wins aligning with modest price gains, but one strong cost-savings study coincided with a notable negative reaction.

Recent Company History

Over the past two months, DarioHealth reported multiple clinically focused and commercial milestones. On Nov 24, 2025, a JMIR study highlighted $5,077 annual cost savings per user but saw a -7.23% move. Subsequent news in early December on client wins and blood pressure outcomes produced small positive reactions of 0.76% and 1.27%. The Dec 10, 2025 DarioIQ™ AI launch generated a stronger 4.11% gain. Today’s evidence-base milestone extends this pattern of clinically oriented, outcomes-focused disclosures.

Regulatory & Risk Context

Active S-3 Shelf

Shelf Active

Active S-3 Shelf Registration 2025-10-20

An effective S-3 resale registration filed on Oct 20, 2025 covers up to 2,713,180 shares held by selling stockholders. The company bears registration expenses and does not receive proceeds from these sales, which can occur via various pricing and transaction structures.

Market Pulse Summary

This announcement reinforces DarioHealth’s strategy of competing on clinical proof, with more than 1...

Analysis

This announcement reinforces DarioHealth’s strategy of competing on clinical proof, with more than 100 peer‑reviewed and rigorously reviewed studies, including longitudinal work up to 2 years. It adds to a series of outcomes‑oriented publications and client wins in late 2025. Against this, investors may track revenue trends (Q3 at $5,007k with a net loss of $10,466k), the $30,617k long‑term loan, and any impact from the registered 2,713,180 shares as they evaluate how the evidence base translates into financial performance.

Key Terms

peer-reviewed, longitudinal, hbA1c, cardiometabolic, +1 more

5 terms

peer-reviewed medical

"peer-reviewed journal publications and peer-reviewed conference abstracts"

Peer-reviewed means a study, report or paper has been examined and approved by independent experts in the same field before publication, like having multiple qualified inspectors check a building plan. For investors, peer review signals that methods and conclusions have passed scrutiny beyond the author’s claims, making scientific, clinical or technical findings more reliable and reducing the chance that decisions or valuation are based on unchecked or flawed evidence.

longitudinal medical

"Longitudinal designs, with some studies spanning up to two years"

Longitudinal describes observations or data collected from the same subjects or entities repeatedly over time, tracking how things change rather than a single snapshot. For investors it matters because longitudinal information reveals trends, persistence, and potential cause-and-effect (for example in sales, safety outcomes, or earnings), helping distinguish short-term noise from meaningful long-term shifts—like watching a plant grow rather than looking at a single photo.

hbA1c medical

"measured HbA1c improvement – not simply modeled or estimated results"

A1c (HbA1c) is a blood test that measures how much sugar has stuck to red blood cells over the past two to three months, giving a single number that reflects average blood glucose control—think of it as a running average score for blood sugar. Investors watch A1c because it’s a common clinical measure used to judge whether diabetes drugs, devices or care programs work, influence regulatory approvals, treatment guidelines and market demand.

cardiometabolic medical

"how cardiometabolic, behavioral health and musculoskeletal needs intersect"

Cardiometabolic describes health conditions that affect the heart and the body’s metabolism—most commonly heart disease, high blood pressure, type 2 diabetes and obesity—that often occur together and share common causes. Investors care because these linked conditions drive large, predictable demand for drugs, medical devices and long-term care, and changes in treatment options, guidelines or costs can materially affect healthcare company revenues and government spending much like a problem in an engine and its fuel system impacts the whole vehicle.

musculoskeletal medical

"cardiometabolic, behavioral health and musculoskeletal needs intersect"

Musculoskeletal relates to the system of bones, muscles, joints, and tissues that support and move the body. It is important to investors because issues or changes in this system can impact the health and productivity of individuals, potentially affecting industries such as healthcare, pharmaceuticals, and insurance. Understanding musculoskeletal health helps gauge broader trends in healthcare spending and workforce well-being.

AI-generated analysis. Not financial advice.

Growing body of peer-reviewed publications and rigorously reviewed conference research reinforces Dario's position as trusted partner for organizations seeking to reduce cost, improve outcomes and simplify digital health delivery

NEW YORK, Jan. 21, 2026 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO) (the "Company", "DarioHealth" or "Dario"), a leader in global digital health, today announced that it has surpassed 100 scientific studies, including peer-reviewed journal publications and peer-reviewed conference abstracts, marking a significant milestone in the Company's commitment to delivering rigorously validated outcomes for employers, health plans and their members.

Reaching this threshold places Dario among the top tier of digital health vendors by volume and depth of  scientifically reviewed evidence, an important differentiator as self-insured employers, consultants and health plans increasingly demand rigorous proof of measurable impact – not merely engagement metrics or modeled results.

Compared with industry peers, Dario's body of published research reflects one of the most extensive and mature evidence bases in digital health and includes a substantial number of independent, third party investigator-initiated studies.

Beyond scale, Dario's research is distinguished by several characteristics that matter directly to purchasers of digital health solutions:

• Large study populations, reflecting real employer and health plan member bases
• Longitudinal designs, with some studies spanning up to two years
• Replication across outcomes, with multiple studies validating key metrics
• Independent validations, including analyses conducted entirely by third-party researchers
• Directly observed outcomes, such as actual claims reduction and measured HbA1c improvement – not simply modeled or estimated results
• Multi-condition evaluations, reflecting how cardiometabolic, behavioral health and musculoskeletal needs intersect in real populations

"For employers and health plans, evidence and scientific rigor are no longer optional – they are foundational," said Omar Manejwala, MD, Chief Medical Officer at Dario.  "Crossing the 100-study milestone demonstrates that Dario's outcomes are durable, repeatable and supported by a broad and credible body of scientific research."

As healthcare purchasers shift toward value-based decision-making and vendor consolidation, Dario's expanding portfolio of peer-reviewed publications and conference-presented research, published on highly regarded platforms such as the Journal of Medical Internet Research and other leading peer-reviewed medical journals, underscores its role as a trusted, outcomes-driven partner capable of delivering measurable impact at scale.

About DarioHealth Corp. (NASDAQ: DRIO)

DarioHealth Corp. (NASDAQ: DRIO) is a leading digital health company revolutionizing how people with chronic conditions manage their health through a user-centric, multi-chronic condition digital therapeutics platform. Dario's platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain and behavioral health.

Dario's user-centric platform offers people continuous and customized care for their health, disrupting the traditional episodic approach to healthcare. This approach empowers people to holistically adapt their lifestyles for sustainable behavior change, driving exceptional user satisfaction, retention and results and making the right thing to do the easy thing to do.

Dario provides its highly user-rated solutions globally to health plans and other payers, self-insured employers, providers of care and consumers. To learn more about Dario and its digital health solutions, or for more information, visit http://dariohealth.com.

Cautionary Note Regarding Forward-Looking Statements

This news release and the statements of representatives and partners of DarioHealth Corp. related thereto contain or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not statements of historical fact may be deemed to be forward-looking statements. For example, the Company is using forward-looking statements in this press release when it discusses its expectations regarding continued expansion of its scientific evidence base and future research publications, its belief regarding the durability, repeatability, and scalability of clinical and economic outcomes demonstrated in published studies, anticipated demand from employers, consultants, and health plans for evidence-based digital health solutions, its expectation that published research will support broader adoption, future collaborations, and vendor consolidation opportunities, and its belief regarding its ability to deliver measurable clinical and cost outcomes across multiple conditions . Without limiting the generality of the foregoing, words such as "plan," "project," "potential," "seek," "may," "will," "expect," "believe," "anticipate," "intend," "could," "estimate" or "continue" are intended to identify forward-looking statements. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect the Company's results include, but are not limited to, regulatory approvals, product demand, market acceptance, impact of competitive products and prices, product development, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks, and the risks associated with the adequacy of existing cash resources. Additional factors that could cause or contribute to differences between the Company's actual results and forward-looking statements include, but are not limited to, those risks discussed in the Company's filings with the U.S. Securities and Exchange Commission. Readers are cautioned that actual results (including, without limitation, the timing for and results of the Company's commercial and regulatory plans for Dario™ as described herein) may differ significantly from those set forth in the forward-looking statements. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

DarioHealth Corporate Contacts

Michael Lipari
SVP Corporate Development
irteam@dariohealth.com
+1-201-785-6310

Rob Halpern
SVP Marketing
irteam@dariohealth.com

Logo - http://mma.prnewswire.com/media/544126/DarioHealth_Logo.jpg

View original content:https://www.prnewswire.com/news-releases/dario-surpasses-100-scientific-studies-cementing-leadership-among-digital-healths-most-evidence-based-platforms-302665906.html

SOURCE DarioHealth Corp.

FAQ

What milestone did DarioHealth (DRIO) announce on Jan 21, 2026?

DarioHealth announced it surpassed 100 peer-reviewed studies and conference abstracts.

How does DarioHealth's (DRIO) research address study duration?

The research portfolio includes longitudinal designs, with some studies spanning up to two years.

Does DarioHealth (DRIO) have independent validations in its evidence base?

Yes; the portfolio includes a substantial number of independent third-party investigator-initiated studies.

What kinds of outcomes are reported in DarioHealth's (DRIO) studies?

Studies report directly observed outcomes such as actual claims reduction and measured HbA1c improvement.

Why is the 100-study milestone important for buyers of digital health, and how does it affect DRIO?

Reaching 100 studies signals a mature evidence base that may help employers and health plans prioritize DRIO for measurable, outcomes-driven solutions over engagement-only vendors.

Where have DarioHealth (DRIO) studies been published or presented?

Dario's research has been published or presented in peer-reviewed outlets including the Journal of Medical Internet Research and other leading medical journals and conferences.